Immunic Therapeutics
Germany - GrafelfingBiotechnology
Focus: Immunic Therapeutics is a Germany-based public biotech company focused on small-molecule immunology and neurology therapeutics. The company operates across neurology, infectious diseases, oncology, and immunology with a diversified pipeline in mid-to-late stage development.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Immunic Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Immunic Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Immunic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT05124795IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer
Phase 1Help build intelligence for Immunic Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.